公开(公告)号：EP3092216B1

公开(公告)日：2018-12-12

申请号：EP15700817.8

申请日：2015-01-05

申请人： Bristol-Myers Squibb Company

发明人： DUAN, Jingwu ,  DHAR, T. G. Murali ,  JIANG, Bin ,  LU, Zhonghui ,  KARMAKAR, Ananta ,  GUPTA, Arun Kumar ,  WEIGELT, Carolyn A.

IPC分类号： C07D213/04 ,  C07D309/08 ,  C07D231/14 ,  C07D401/02 ,  C07D403/04 ,  C07D237/06 ,  C07D405/02 ,  C07D239/28 ,  C07C317/00 ,  C07D241/24 ,  C07D249/04 ,  C07D471/04 ,  C07D205/04 ,  C07D207/277 ,  C07D277/60 ,  C07D295/00 ,  C07D211/36 ,  A61K31/33 ,  A61K31/10 ,  A61P29/00

CPC分类号： C07C317/14 ,  C07C317/20 ,  C07C317/22 ,  C07C317/30 ,  C07C317/32 ,  C07C317/44 ,  C07C317/46 ,  C07C317/50 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07D205/04 ,  C07D211/36 ,  C07D211/62 ,  C07D213/30 ,  C07D213/40 ,  C07D213/56 ,  C07D213/75 ,  C07D213/81 ,  C07D213/85 ,  C07D231/12 ,  C07D237/08 ,  C07D239/38 ,  C07D241/12 ,  C07D257/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D285/06 ,  C07D295/108 ,  C07D295/155 ,  C07D295/18 ,  C07D295/185 ,  C07D295/20 ,  C07D295/22 ,  C07D303/06 ,  C07D303/34 ,  C07D305/14 ,  C07D309/04 ,  C07D309/14 ,  C07D317/44 ,  C07D319/20 ,  C07D401/04 ,  C07D471/04 ,  C07D471/10

摘要： Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

公开(公告)号：EP3166569B1

公开(公告)日：2018-11-28

申请号：EP15736258.3

申请日：2015-07-09

申请人： Ivoclar Vivadent AG ,  Technische Universität Wien

发明人： MOSZNER, Norbert ,  FISCHER, Urs-Karl ,  LAMPARTH, Iris ,  BURTSCHER, Peter ,  LISKA, Robert ,  GORSCHE, Christian ,  SEIDLER, Konstanze ,  GAUSS, Paul

IPC分类号： A61K6/083

CPC分类号： A61K6/0052 ,  A61K6/083 ,  C07C317/28 ,  C07C317/44 ,  C07C323/52 ,  C07F9/4015

公开(公告)号：EP3252039A4

公开(公告)日：2018-07-25

申请号：EP16742705

申请日：2016-01-25

申请人： BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD

发明人： BEIJING AN JIAN XI BIO-MEDICAL TECHNOLOGY CO LTD

IPC分类号： C07D209/26 ,  A61K9/00 ,  A61K31/216 ,  A61K31/337 ,  A61K31/405 ,  A61K31/635 ,  A61K31/661 ,  A61K31/704 ,  A61K45/06 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  C07C317/44

CPC分类号： C07D209/26 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/337 ,  A61K31/405 ,  A61K31/635 ,  A61K31/661 ,  A61K31/704 ,  A61K45/06 ,  C07C317/44 ,  C07C2602/08

摘要： Disclosed are a compound as shown by the following formula 1, and a pharmaceutically acceptable salt, an ester, a hydrate and an organic solvate thereof. In the formula (1), the groups R 1 to R 17 are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, carbonyl, hydroxyl, amino, azido, carboxyl and C 1 -C 8 alkylsulfinyl, respectively; and X is a carbon or nitrogen atom; Y is selected from the following groups: a single bond, C 1 -C 8 alkylene, C 6 -C 20 arylene and C 4 -C 20 heteroarylene; and n is an integer from 5 to 20. Also provided in the present invention are a pharmaceutical composition containing the compound, and use thereof in the field of tumor therapy.

公开(公告)号：EP3217790A4

公开(公告)日：2018-07-18

申请号：EP15858283

申请日：2015-11-09

申请人： MIRTECH INC

发明人： MIR NAZIR

IPC分类号： A01N3/00 ,  A01N25/10 ,  A01N25/18 ,  A01N25/28 ,  A01N27/00 ,  B65D81/24 ,  C07C7/10 ,  C07D251/12 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F15/02 ,  C07F15/06

CPC分类号： C07C7/12 ,  A01N3/00 ,  A01N25/10 ,  A01N27/00 ,  B01J20/226 ,  C07C7/10 ,  C07C53/06 ,  C07C55/02 ,  C07C317/14 ,  C07C317/44 ,  C07D251/12 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F15/02 ,  C07F15/06 ,  A01N25/18 ,  A01N25/28

摘要： Disclosed are adsorption complexes that include 1-methylcyclopropene (1-MCP) and a metal coordination polymer network (MCPN), wherein the MCPN is a porous material, and the 1-MCP is adsorbed into the MCPN. Also disclosed are kits for containing 1-MCP that include the adsorption complex in a 1-MCP-impermeable package. Also disclosed are methods of releasing 1-methylcyclopropene (1-MCP) from the kit that include the application of aqueous fluids, heat, and/or pressure.

公开(公告)号：EP3215141A4

公开(公告)日：2018-06-06

申请号：EP15856241

申请日：2015-11-05

申请人： FLEXUS BIOSCIENCES INC

发明人： BECK HILARY PLAKE ,  JAEN JUAN CARLOS ,  OSIPOV MAKSIM ,  POWERS JAY PATRICK ,  REILLY MAUREEN KAY ,  SHUNATONA HUNTER PAUL ,  WALKER JAMES ROSS ,  ZIBINSKY MIKHAIL ,  BALOG JAMES AARON ,  WILLIAMS DAVID K ,  GUO WEIWEI

IPC分类号： A61K31/16 ,  A61P35/00 ,  C07C13/02 ,  C07C13/16

CPC分类号： A61K31/195 ,  A61K31/167 ,  A61K31/426 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/55511 ,  A61P35/00 ,  C07C233/15 ,  C07C233/29 ,  C07C233/66 ,  C07C235/26 ,  C07C235/36 ,  C07C235/38 ,  C07C237/20 ,  C07C237/22 ,  C07C255/57 ,  C07C255/60 ,  C07C317/40 ,  C07C317/44 ,  C07C321/28 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/27 ,  C07D213/56 ,  C07D213/75 ,  C07D231/12 ,  C07D239/42 ,  C07D277/30 ,  C07D295/15 ,  C07D295/155 ,  C07D309/04 ,  C07D309/06 ,  C07D317/46 ,  Y02A50/41 ,  Y02A50/412 ,  A61K2300/00

摘要： Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune -related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

公开(公告)号：EP2817286B1

公开(公告)日：2018-06-06

申请号：EP13764613.9

申请日：2013-03-22

申请人： Pitney Pharmaceuticals Pty Limited

发明人： MORRIS, David Lawson

IPC分类号： A61K31/277 ,  A61P35/00 ,  C07C255/29 ,  C07C317/14 ,  C07C317/44 ,  C07C323/62

CPC分类号： A61K31/277 ,  A61K31/275 ,  C07C255/29 ,  C07C317/44 ,  C07C323/62

摘要： The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of cancer.

公开(公告)号：EP3303292A1

公开(公告)日：2018-04-11

申请号：EP16730288.4

申请日：2016-06-03

申请人： Lead Pharma Holding B.V. ,  SANOFI

发明人： CALS, Joseph Maria Gerardus Barbara ,  DE KIMPE, Vera ,  NABUURS, Sander Bernardus ,  CADICAMO, Cosimo Damiano ,  LEMMERS, Jaap Gerardus Henricus

IPC分类号： C07D213/75 ,  C07D231/12 ,  C07D333/36 ,  C07D233/61 ,  C07C311/20 ,  C07C317/32 ,  C07D409/04 ,  C07D249/08 ,  C07D263/32 ,  C07D271/06 ,  C07D277/46 ,  A61K31/10 ,  A61K31/18 ,  A61P29/00 ,  A61P37/00

CPC分类号： C07C317/32 ,  A61K31/167 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4402 ,  A61K31/4436 ,  A61K31/4439 ,  C07C311/20 ,  C07C317/44 ,  C07C2601/02 ,  C07D213/72 ,  C07D213/75 ,  C07D231/12 ,  C07D233/61 ,  C07D249/08 ,  C07D263/32 ,  C07D271/06 ,  C07D277/46 ,  C07D277/54 ,  C07D333/36 ,  C07D409/04 ,  C07D417/12 ,  Y02A50/409

摘要： The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof wherein the variables are as defined in the claims. The compounds can be used as inhibitors of ROR³ and are useful for the treatment of ROR³ mediated diseases.

公开(公告)号：EP3187514A4

公开(公告)日：2018-04-04

申请号：EP15835738

申请日：2015-08-25

申请人： TOKUYAMA DENTAL CORP

发明人： INAKI YOSHITAKA ,  SAKATA EIBU ,  SUZUKI TAKESHI

IPC分类号： C07C69/76 ,  C07C69/83 ,  C07C69/94 ,  C07C235/12 ,  C07C271/16 ,  C07C317/44 ,  C07C323/62 ,  C08F20/30

CPC分类号： C07C69/76 ,  C07C69/94 ,  C07C271/16 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/14 ,  C08F20/30

摘要： Provided are: a polymerizable monomer excellent in mechanical strength of its cured product and excellent also in handling property with low viscosity even under a room temperature environment, specifically, a polymerizable monomer, which is represented by the following general formula (1): in the general formula (1), X represents a divalent group, Ar 1 and Ar 2 each represent an aromatic group having a valence selected from divalence to tetravalence, and may be identical to or different from each other, L 1 and L 2 each represent a hydrocarbon group having a main chain with a number of atoms within a range of from 2 to 60 and having a valence selected from divalence to tetravalence, and may be identical to or different from each other, R 1 and R 2 each represent a hydrogen atom or a methyl group, and m1, m2, n1, and n2 each represent an integer selected from a range of from 1 to 3; and a curable composition and a resin member each using the polymerizable monomer.

公开(公告)号：EP3294706A1

公开(公告)日：2018-03-21

申请号：EP16729646

申请日：2016-05-06

申请人： TAKEDA PHARMACEUTICALS CO

发明人： KOBAYASHI TOSHITAKE ,  SAITOH MORIHISA ,  WADA YASUFUMI ,  NARA HIROSHI ,  NEGORO NOBUYUKI ,  KATOH TAISUKE ,  YAMASAKI MASASHI ,  TANAKA TAKAHIRO ,  KITAMOTO NAOMI

IPC分类号： C07C317/46 ,  A61K31/216 ,  A61K31/357 ,  A61P1/16 ,  A61P25/02 ,  C07C317/44 ,  C07D309/28 ,  C07D317/72

CPC分类号： C07D317/72 ,  C07C317/12 ,  C07C317/44 ,  C07C317/46 ,  C07C2601/16 ,  C07C2602/08 ,  C07D309/28

摘要： wherein, each symbol is explained in greater detail in the specification.

公开(公告)号：EP2802560B1

公开(公告)日：2018-03-07

申请号：EP13700986.6

申请日：2013-01-08

申请人： Studiengesellschaft Kohle mbH

发明人： LIST, Benjamin ,  CORIC, Ilija ,  LIAO, Saihu

IPC分类号： C07F9/6571 ,  C07C315/02 ,  B01J31/02 ,  C07F9/6574 ,  C07B45/04 ,  C07B53/00 ,  C07D493/10

CPC分类号： C07C315/02 ,  B01J31/0258 ,  B01J31/0264 ,  B01J2231/70 ,  C07B45/04 ,  C07B53/00 ,  C07B2200/07 ,  C07C2601/14 ,  C07C2602/08 ,  C07D493/10 ,  C07F9/657154 ,  C07F9/65744 ,  C07C317/14 ,  C07C317/22 ,  C07C317/12 ,  C07C317/04 ,  C07C317/44

摘要： The present invention relates to a process for the asymmetric oxidation of organic compounds, particularly metal-free, with peroxide compounds in the presence of a chiral Brønsted acid catalyst. In one detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral imidodiphosphate catalyst. In another detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral phosphoric acid catalyst.